<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">KOSHIYAMA, MASAFUMI</style></author><author><style face="normal" font="default" size="100%">KINEZAKI, MASANORI</style></author><author><style face="normal" font="default" size="100%">UCHIDA, TAKAFUMI</style></author><author><style face="normal" font="default" size="100%">SUMITOMO, MASAHIRO</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Chemosensitivity Testing of a Novel Platinum Analog, Nedaplatin (254-S), in Human Gynecological Carcinomas: a Comparison with Cisplatin</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2005</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2005-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">4499-4502</style></pages><volume><style face="normal" font="default" size="100%">25</style></volume><issue><style face="normal" font="default" size="100%">6C</style></issue><abstract><style  face="normal" font="default" size="100%">Background: The tetrazolium dye (MTT) assay is useful for predicting chemosensitivity. Materials and Methods: Using the MTT assay, an in vitro chemosensitivity test was designed for nedaplatin (cis-diammine glycolato platinum; 254-S) and the results were compared with the sensitivity to cisplatin in 137 resected gynecological carcinomas. Results: The mean tumor inhibition rate [I.R.; %] for nedaplatin was equal or superior to cisplatin in 15 cervical [70.7% vs. 63.9%], 65 ovarian [61.7% vs. 54.8%] and 57 endometrial carcinomas [52.1% vs. 47.7%]. In ovarian carcinomas, the I.R.s for nedaplatin were significantly higher than cisplatin in poorly-differentiated, serous and endometrioid adenocarcinomas [80.7% vs. 56.4% (p&lt;0.05), 77.0% vs. 64.9% (p&lt;0.01), and 68.2% vs. 54.6% (p&lt;0.05), respectively]. Conclusion: Our data suggest that nedaplatin has equivalent or superior antitumor activity to cisplatin in cervical, ovarian and endometrial carcinomas. In particular, nedaplatin showed a siginificantly better antitumor activity among the histological subtypes of ovarian carcinomas. Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved</style></abstract></record></records></xml>